WUXI
WXINext catalyst
BGM0504 Administered
Type 2 Diabetes Mellitus (T2DM)
Get an email about WXI's next catalysts
Track WUXI (WXI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (Phase 3 readout, company event, Phase 2 readout).See the timeline
6 upcoming, 0 past
BGM0504 Administered Phase 3 Est. Readout
Estimated primary completion for BGM0504 Administered trial (NCT06716216) in Type 2 Diabetes Mellitus (T2DM). Topline data typically follows completion by weeks to months.
SourceBGM0504 Administered Phase 3 Est. Readout
Estimated primary completion for BGM0504 Administered trial (NCT06716203) in Type 2 Diabetes Mellitus (T2DM). Topline data typically follows completion by weeks to months.
SourceMesenchymal Stem Cells Phase 3 Est. Readout
Primary completion for Mesenchymal Stem Cells trial (NCT06570291) in Knee Osteoarthritis
SourceOther
Thermo Fisher Scientific is closing its chemical analysis manufacturing facility in Franklin, MA due to current customer demands, while WuXi has signed a contract with Vertex.
D3S-001 Phase 2 Est. Readout
Primary completion for D3S-001 trial (NCT05410145) in KRAS P.G12C
SourceNWRD08 administered by electroporation Phase 2 Est. Readout
Estimated primary completion for NWRD08 administered by electroporation trial (NCT07175662) in High-grade Squamous Intraepithelial Lesion (HSIL). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
BGM0504
Overweight or Obesity
Guideline-directed medical therapy (GDMT) for heart failure
Pulmonary Hypertension
Mesenchymal Stem Cells
Knee Osteoarthritis
CU-20101 treatment for Moderate to Severe Glabellar Striae
Glabellar Frown Lines
CU-40102 Spray
AGA
A+C Vaccine
Group A, C Polysaccharide Meningitis
A+C+hib Conjugate Vaccine
Meningitis
ESAT6-CFP10 in left arm and TB-PPD in right arm
Tuberculosis
Paclitaxel and Cisplatin
Stage III Esophageal Squamous Cell Carcinoma
Dapagliflozin+Standard Treatment,washout period ，then Standard Treatment alone for12 weeks
Pediatric Hereditary Kidney Diseases
BGM0504 Administered
Type 2 Diabetes Mellitus (T2DM)
Gemcitabine +Carboplatin
Non-small Cell Lung Cancer
BGM0504 injection administered subcutaneously a week
Overweight or Obesity
Pemetrexed (1)
Leptomeningeal Metastases
MSC-IFNα
Locally Advanced or Metastatic Solid Tumors
RMP-A03 - Dose 2
Pterygium
RMP-A03 - Dose 1
Pterygium
1.Abiraterone Acetate Tablets
Prostatectomy
D3S-001
KRAS P.G12C
CU-20401
Safety
Subcutaneous injection of CU-20401
Efficacy and Safety
D3S-002
Advanced Solid Tumors With MAPK Pathway Mutations
PEG-somatropin
Dwarfism
NWRD08 administered by electroporation
High-grade Squamous Intraepithelial Lesion (HSIL)
Selinexor
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Anti-PD-1 monoclonal antibody
Locally Advanced or Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BGM0504 | Phase 3 | Overweight or Obesity | - | - |
Guideline-directed medical therapy (GDMT) for heart failure | Phase 3 | Pulmonary Hypertension | - | - |
Mesenchymal Stem Cells | Phase 3 | Knee Osteoarthritis | - | - |
CU-20101 treatment for Moderate to Severe Glabellar Striae | Phase 3 | Glabellar Frown Lines | - | - |
CU-40102 Spray | Phase 3 | AGA | - | - |
A+C Vaccine | Phase 3 | Group A, C Polysaccharide Meningitis | - | - |
A+C+hib Conjugate Vaccine | Phase 3 | Meningitis | - | - |
ESAT6-CFP10 in left arm and TB-PPD in right arm | Phase 3 | Tuberculosis | - | - |
Paclitaxel and Cisplatin | Phase 3 | Stage III Esophageal Squamous Cell Carcinoma | - | - |
Dapagliflozin+Standard Treatment,washout period ，then Standard Treatment alone for12 weeks | Phase 3 | Pediatric Hereditary Kidney Diseases | - | - |
BGM0504 Administered | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
Gemcitabine +Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
BGM0504 injection administered subcutaneously a week | Phase 3 | Overweight or Obesity | - | - |
Pemetrexed (1) | Phase 2 | Leptomeningeal Metastases | - | - |
MSC-IFNα | Phase 2 | Locally Advanced or Metastatic Solid Tumors | - | - |
RMP-A03 - Dose 2 | Phase 2 | Pterygium | - | - |
RMP-A03 - Dose 1 | Phase 2 | Pterygium | - | - |
1.Abiraterone Acetate Tablets | Phase 2 | Prostatectomy | - | - |
D3S-001 | Phase 2 | KRAS P.G12C | - | - |
CU-20401 | Phase 2 | Safety | - | - |
Subcutaneous injection of CU-20401 | Phase 2 | Efficacy and Safety | - | - |
D3S-002 | Phase 2 | Advanced Solid Tumors With MAPK Pathway Mutations | - | - |
PEG-somatropin | Phase 2 | Dwarfism | - | - |
NWRD08 administered by electroporation | Phase 2 | High-grade Squamous Intraepithelial Lesion (HSIL) | - | - |
Selinexor | Phase 2 | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | - | - |
Anti-PD-1 monoclonal antibody | Phase 2 | Locally Advanced or Metastatic Solid Tumors | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in WUXI's drug pipeline?→
CatalystAlert tracks 26 drug candidates in WUXI's (WXI) pipeline across Phase 3, Phase 2. Its lead program is BGM0504 Administered (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is WUXI's next FDA catalyst?→
WUXI's (WXI) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track WXI biotech catalysts?→
Add WXI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow WUXI's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.